– USA, NV – Secura Bio, Inc., an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, announced the appointment of Dr. Patrick Vink (MD) as Chairman of its Board of Directors bringing over 35 years of industry experience.
About Dr. Patrick Vink
Dr. Patrick Vink serves as Chairman and Board member of several public and private biopharma companies, both in the U.S. and in Europe, including F2G Ltd and Essential Pharma. Throughout his Board tenures, he has played an active role in initial public offerings, achieving meaningful development, regulatory and commercial milestones, and facilitating geographic expansions. As a Board member of Amryt Pharma, he was involved in the recent sale to Chiesi Farmaceutici for over $1.4 billion, and as Chair of the Board of Biognosys, he guided their transaction with Bruker in 2023.
Dr. Vink previously served as EVP and CEO at Cubist, Inc., a leader in the acute care hospital market. In this role, Dr. Vink oversaw all worldwide commercial and technical operations until the successful acquisition of Cubist by Merck for $9.5 billion in 2015. Before Cubist, Dr. Vink held several key leadership roles across the biopharmaceutical industry, including head of the Global Hospital Business at Mylan Inc., the Global Hospital Business at Sandoz (a division of Novartis), and the head of the International Business at Biogen.
Dr. Patrick Vink holds an M.D. from the University of Leiden and an MBA from the University of Rochester.
About Secura Bio, Inc.
Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients. Its product, COPIKTRA, is currently approved for the treatment of multiple B-cell malignancies and is also being investigated for the treatment of peripheral T-cell lymphoma, for which it has received Fast Track status in the United States and is being investigated in combination with other agents through investigator-sponsored studies.
For more information: https://www.securabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.